Cognetivity Neurosciences Ltd is developing a platform technology comprising of a visual stimulus based diagnostic test and artificial intelligence tools to support the early detection and monitoring of cognitive impairment in neurodegenerative diseases, with initial emphasis on dementia in Alzheimer's disease and mild cognitive impairment, a difficult-to-diagnose, "pre-dementia" condition.
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -43.18% per trade.